10x Genomics, Inc. TXG EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s EPS (diluted)?
- 10x Genomics, Inc. (TXG) reported EPS (diluted) of -$0.10 in Q1 2026.
- How has 10x Genomics, Inc.'s EPS (diluted) changed year-over-year?
- 10x Genomics, Inc.'s EPS (diluted) increased by 64.3% year-over-year, from -$0.28 to -$0.10.
- What is the long-term trend for 10x Genomics, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), 10x Genomics, Inc.'s EPS (diluted) has grown at a -9.9% compound annual growth rate (CAGR), from -$0.53 to -$0.35.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.